Parkside Financial Bank & Trust Cuts Stock Holdings in Danaher Co. (NYSE:DHR)

Parkside Financial Bank & Trust cut its stake in shares of Danaher Co. (NYSE:DHR) by 1.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,922 shares of the conglomerate’s stock after selling 77 shares during the period. Parkside Financial Bank & Trust’s holdings in Danaher were worth $980,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Patrick M Sweeney & Associates Inc. increased its stake in shares of Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after acquiring an additional 40 shares during the period. Trust Co of Kansas raised its stake in shares of Danaher by 4.1% in the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after buying an additional 40 shares in the last quarter. Abacus Planning Group Inc. lifted its holdings in shares of Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after buying an additional 40 shares during the period. ST Germain D J Co. Inc. boosted its stake in Danaher by 1.4% during the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after buying an additional 41 shares in the last quarter. Finally, Godsey & Gibb Inc. grew its holdings in Danaher by 3.0% during the first quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock worth $360,000 after acquiring an additional 42 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Up 1.1 %

NYSE:DHR traded up $2.81 on Friday, hitting $267.52. 562,414 shares of the company’s stock traded hands, compared to its average volume of 2,774,937. The firm has a 50-day moving average price of $260.98 and a 200-day moving average price of $255.61. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company has a market cap of $198.15 billion, a PE ratio of 45.52, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.05 EPS. Equities analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,659 shares of company stock worth $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DHR. TD Cowen upped their price target on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Jefferies Financial Group assumed coverage on shares of Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price on the stock. Robert W. Baird raised their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Bank of America upped their price target on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Finally, StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.